166 related articles for article (PubMed ID: 21516345)
1. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis.
Musiał K; Zwolińska D
Apoptosis; 2011 Jul; 16(7):653-9. PubMed ID: 21516345
[TBL] [Abstract][Full Text] [Related]
2. Hsp27 as a marker of cell damage in children on chronic dialysis.
Musiał K; Zwolińska D
Cell Stress Chaperones; 2012 Nov; 17(6):675-82. PubMed ID: 22528051
[TBL] [Abstract][Full Text] [Related]
3. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease.
Musiał K; Zwolińska D
Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinases as novel stress markers in children and young adults on chronic dialysis.
Musiał K; Zwolińska D
Cell Stress Chaperones; 2011 Mar; 16(2):163-71. PubMed ID: 20853162
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
6. New markers of apoptosis in children on chronic dialysis.
Musiał K; Zwolińska D
Apoptosis; 2013 Jan; 18(1):77-84. PubMed ID: 23054081
[TBL] [Abstract][Full Text] [Related]
7. [Matrix metalloproteinases and their tissue inhibitors in children and young adults on chronic hemodialysis--preliminary results].
Musiał K; Makulska I; Zwolńska D
Pol Merkur Lekarski; 2009 Apr; 26(154):290-3. PubMed ID: 19580190
[TBL] [Abstract][Full Text] [Related]
8. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
9. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.
Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z
Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884
[TBL] [Abstract][Full Text] [Related]
10. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
[TBL] [Abstract][Full Text] [Related]
11. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
12. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
[TBL] [Abstract][Full Text] [Related]
13. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.
Liphaus BL; Kiss MHB; Carrasco S; Palmeira P; Goldenstein-Schainberg C; Carneiro-Sampaio M
Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
15. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.
Fathi M; Amirghofran Z; Shahriari M
Med Oncol; 2012 Sep; 29(3):2046-52. PubMed ID: 21528407
[TBL] [Abstract][Full Text] [Related]
16. Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients.
Lapinski TW; Kowalczuk O; Prokopowicz D; Chyczewski L
World J Gastroenterol; 2004 Dec; 10(24):3650-3. PubMed ID: 15534924
[TBL] [Abstract][Full Text] [Related]
17. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.
Boroumand-Noughabi S; Sima HR; Ghaffarzadehgan K; Jafarzadeh M; Raziee HR; Hosseinnezhad H; Moaven O; Rajabi-Mashhadi MT; Azarian AA; Mashhadinejad M; Tavakkol-Afshari J
BMC Cancer; 2010 Jun; 10():275. PubMed ID: 20534173
[TBL] [Abstract][Full Text] [Related]
18. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand.
Matsuno H; Yudoh K; Watanabe Y; Nakazawa F; Aono H; Kimura T
J Rheumatol; 2001 Jan; 28(1):22-8. PubMed ID: 11196534
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of the sFas/sFasL system in psoriatic patients.
Myśliwiec H; Baran A; Myśliwiec P; Górska M; Flisiak I
Adv Med Sci; 2015 Mar; 60(1):64-8. PubMed ID: 25437350
[TBL] [Abstract][Full Text] [Related]
20. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance.
Cosson E; Bringuier AF; Paries J; Guillot R; Vaysse J; Attali JR; Feldmann G; Valensi P
Diabetes Metab; 2005 Feb; 31(1):47-54. PubMed ID: 15803113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
